BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 9028361)

  • 1. Adenocarcinoma of the cervix. Expression and clinical significance of estrogen and progesterone receptors.
    Fujiwara H; Tortolero-Luna G; Mitchell MF; Koulos JP; Wright TC
    Cancer; 1997 Feb; 79(3):505-12. PubMed ID: 9028361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.
    Regan MM; Viale G; Mastropasqua MG; Maiorano E; Golouh R; Carbone A; Brown B; Suurküla M; Langman G; Mazzucchelli L; Braye S; Grigolato P; Gelber RD; Castiglione-Gertsch M; Price KN; Coates AS; Goldhirsch A; Gusterson B;
    J Natl Cancer Inst; 2006 Nov; 98(21):1571-81. PubMed ID: 17077359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study of estrogen receptor, progesterone receptor, and the estrogen-regulated Mr 24,000 protein in patients with carcinomas of the endometrium and cervix.
    Ciocca DR; Puy LA; Fasoli LC
    Cancer Res; 1989 Aug; 49(15):4298-304. PubMed ID: 2743317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Expression of estrogen and progesterone receptors and oncoprotein HER-2 as a marker for clinical course and outcome in endometrioid adenocarcinoma of the uterine body (immunohistologic study)].
    Samsonova EA; Maksimova NA; Urmancheeva AF; Pozharisskiĭ KM
    Vopr Onkol; 2004; 50(2):196-201. PubMed ID: 15176223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Steroid hormone receptors in mammary carcinoma. Immunohistochemical detection and prognostic significance].
    Reiner A; Neumeister B; Reiner G; Jakesz R; Kolb R; Schemper M; Spona J
    Zentralbl Pathol; 1991; 137(3):233-41. PubMed ID: 1657132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype.
    Rakha EA; El-Sayed ME; Green AR; Paish EC; Powe DG; Gee J; Nicholson RI; Lee AH; Robertson JF; Ellis IO
    J Clin Oncol; 2007 Oct; 25(30):4772-8. PubMed ID: 17876012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormone receptors and disease-free survival in breast cancer: impact of increasing threshold levels.
    Di Fronzo G; Coradini D; Cappelletti V; Miodini P; Granata G; Schwartz M; Panko WB
    Anticancer Res; 1990; 10(6):1699-705. PubMed ID: 2285244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma.
    Fukuda K; Mori M; Uchiyama M; Iwai K; Iwasaka T; Sugimori H
    Gynecol Oncol; 1998 Jun; 69(3):220-5. PubMed ID: 9648591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Dell'Orto P; Rasmussen BB; Raffoul J; Neven P; Orosz Z; Braye S; Ohlschlegel C; Thürlimann B; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2007 Sep; 25(25):3846-52. PubMed ID: 17679725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-proliferative activity, progesterone receptor status, estrogen receptor level, and clinical outcome of estrogen receptor-positive advanced breast cancer.
    Paradiso A; Tommasi S; Mangia A; Lorusso V; Simone G; De Lena M
    Cancer Res; 1990 May; 50(10):2958-62. PubMed ID: 2334898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical detection of hormone receptors in breast carcinomas (ER-ICA, PgR-ICA): prognostic usefulness and comparison with the biochemical radioactive-ligand-binding assay (DCC).
    Beck T; Weikel W; Brumm C; Wilkens C; Pollow K; Knapstein PG
    Gynecol Oncol; 1994 May; 53(2):220-7. PubMed ID: 8188083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of estrogen and progesterone receptors in non-small-cell lung cancer: immunohistochemical study.
    Su JM; Hsu HK; Chang H; Lin SL; Chang HC; Huang MS; Tseng HH
    Anticancer Res; 1996; 16(6B):3803-6. PubMed ID: 9042261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
    Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
    J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors associated with prognosis in human breast cancer. IV. Progesterone receptors and clinical factors.
    Macías A; Pascual MR; Pérez R; Lage A
    Neoplasma; 1983; 30(5):593-601. PubMed ID: 6656963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17.
    Goss PE; Ingle JN; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Tu D; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Cameron DA; Palmer MJ; Pater JL;
    J Clin Oncol; 2007 May; 25(15):2006-11. PubMed ID: 17452676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endocervical adenocarcinomas with prominent endometrial or endomyometrial involvement simulating primary endometrial carcinomas: utility of HPV DNA detection and immunohistochemical expression of p16 and hormone receptors to confirm the cervical origin of the corpus tumor.
    Yemelyanova A; Vang R; Seidman JD; Gravitt PE; Ronnett BM
    Am J Surg Pathol; 2009 Jun; 33(6):914-24. PubMed ID: 19295407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
    Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J;
    J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can expression of apoptosis genes, bcl-2 and bax, predict survival and responsiveness to chemotherapy in node-negative breast cancer patients?
    Kymionis GD; Dimitrakakis CE; Konstadoulakis MM; Arzimanoglou I; Leandros E; Chalkiadakis G; Keramopoulos A; Michalas S
    J Surg Res; 2001 Aug; 99(2):161-8. PubMed ID: 11469882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.